Nail Psoriasis A Review

被引:66
作者
Tan, Eugene S. T. [1 ]
Chong, Wei-Sheng [1 ]
Tey, Hong Liang [1 ]
机构
[1] Natl Skin Ctr, Singapore 308205, Singapore
关键词
PULSED DYE-LASER; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TAZAROTENE 0.1-PERCENT GEL; TO-SEVERE PSORIASIS; OF-THE-LITERATURE; DOUBLE-BLIND; TOPICAL CYCLOSPORINE; CLINICAL-FEATURES; SEVERITY INDEX; BETAMETHASONE DIPROPIONATE;
D O I
10.2165/11597000-000000000-00000
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Nail psoriasis is common, occurring in up to half of patients with psoriasis and in 90% of patients with psoriatic arthritis. Left untreated, it may progress to debilitating nail disease, which leads to significant functional impairment. The most common clinical signs of nail psoriasis are nail plate pitting and onycholysis. Other classical signs include oil drop discoloration, subungual hyperkeratosis, and splinter hemorrhages. The modified Nail Psoriasis Severity Index (mNAPSI) can be used to grade the severity of nail psoriasis, while the Nail Psoriasis Quality of Life Scale (NPQ10) is a questionnaire that evaluates the impact of nail psoriasis on the patient's functional status and quality of life. Treatment of nail psoriasis should be individualized according to the patient's preferences, severity of nail changes, and presence of skin and/or joint involvement. Both topical and intralesional therapies are safe and effective treatment modalities for nail disease, but are limited by poor adherence and pain, respectively. Systemic therapy such as oral retinoids may be considered for widespread nail disease causing significant morbidity. Among biologic agents, tumor necrosis factor-alpha inhibitors and T-cell-targeted therapies such as ustekinumab may be useful for refractory severe nail psoriasis.
引用
收藏
页码:375 / 388
页数:14
相关论文
共 99 条
[61]   Modification of the nail psoriasis severity index [J].
Parrish, CA ;
Sobera, JO ;
Elewski, BE .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (04) :745-746
[62]  
Parrish Charles A, 2006, J Drugs Dermatol, V5, P339
[63]  
Patsatsi A, J DERMATOLOG TREAT
[64]   Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients [J].
Piraccini, BM ;
Tosti, A ;
Iorizzo, M ;
Misciali, C .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (05) :1000-1005
[65]  
Plunkett A, 1998, Australas J Dermatol, V39, P225, DOI 10.1111/j.1440-0960.1998.tb01478.x
[66]   Instability of topical Ciclosporin emulsion for nail psoriasis [J].
Prins, A. M. A. ;
Vos, K. ;
Franssen, E. J. F. .
DERMATOLOGY, 2007, 215 (04) :362-363
[67]  
Rallis E, 2008, J RHEUMATOL, V35, P544
[68]   Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial [J].
Reich, K ;
Nestle, FO ;
Papp, K ;
Ortonne, JP ;
Evans, R ;
Guzzo, C ;
Li, S ;
Dooley, LT ;
Griffiths, CEM .
LANCET, 2005, 366 (9494) :1367-1374
[69]   Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial [J].
Reich, Kristian ;
Ortonne, Jean-Paul ;
Kerkmann, Urs ;
Wang, Yanxin ;
Saurat, Jean-Hilaire ;
Papp, Kim ;
Langley, Richard ;
Griffiths, Christopher E. M. .
DERMATOLOGY, 2010, 221 (02) :172-178
[70]   Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis [J].
Rich, P ;
Scher, RK .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) :206-212